Select Publications
Journal articles
2025, 'Prognostic Value of Main Pulmonary Artery Diameter in Pulmonary Arterial Hypertension.', Chest, http://dx.doi.org/10.1016/j.chest.2025.02.012
,2025, 'Early Use of Aspirin for Coronary Allograft Prophylaxis in Heart Transplant Recipients', Transplantation, 109, pp. 346 - 351, http://dx.doi.org/10.1097/TP.0000000000005131
,2025, '“A new realization of what I’m able to do”: exercise interventions can impact knowledge, confidence and daily activity for people with pulmonary arterial hypertension (PAH)', Disability and Rehabilitation, http://dx.doi.org/10.1080/09638288.2025.2469777
,2025, 'Thymoma-Induced Severe Biventricular Failure without Myasthenia Gravis: Investigating Tachycardia-Induced Cardiomyopathy', American Journal of Case Reports, 26, http://dx.doi.org/10.12659/AJCR.945796
,2025, 'Assessing Cytomegalovirus (CMV) Viraemia Rates in Intermediate Risk Heart Transplant Patients: Universal Prophylaxis versus Preemptive Therapy', The Journal of Heart and Lung Transplantation, 44, pp. S417 - S417, http://dx.doi.org/10.1016/j.healun.2025.02.896
,2025, 'Experience with an Immunosuppressant Dose Adjustment Plan to Manage Nirmatrelvir/Ritonavir Drug Interactions during COVID-19 Treatment in Cardiothoracic Transplant Recipients', The Journal of Heart and Lung Transplantation, 44, pp. S368 - S368, http://dx.doi.org/10.1016/j.healun.2025.02.789
,2025, 'Role of Human Leukocyte Antigen Eplet Matching in the Development of Cardiac Allograft Vasculopathy and Acute Cellular Rejection in Heart Transplant Recipients', The Journal of Heart and Lung Transplantation, 44, pp. S652 - S653, http://dx.doi.org/10.1016/j.healun.2025.02.1402
,2024, 'Pulsatile Vascular Afterload Measurement Improves Prediction of Right-Sided Heart Dysfunction in Undifferentiated and Left-Sided Pulmonary Hypertension', Journal of the American Heart Association, 13, http://dx.doi.org/10.1161/JAHA.124.034684
,2024, 'Rapid triage and transition to telehealth for heart transplant patients in the COVID-19 pandemic setting', Journal of Telemedicine and Telecare, 30, pp. 1481 - 1486, http://dx.doi.org/10.1177/1357633X231151714
,2024, 'Cost-Effectiveness of Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation in the Australian Health Care System', Heart Lung and Circulation, 33, pp. 1173 - 1183, http://dx.doi.org/10.1016/j.hlc.2024.03.004
,2024, 'Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy', Chest, 165, pp. 967 - 977, http://dx.doi.org/10.1016/j.chest.2023.10.037
,2024, 'Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study', Journal of Medical Economics, 27, pp. 596 - 604, http://dx.doi.org/10.1080/13696998.2024.2328483
,2024, 'Effect of sodium glucose cotransporter 2 inhibition immediately prior to heart transplantation.', JHLT Open, 5, pp. 100088, http://dx.doi.org/10.1016/j.jhlto.2024.100088
,2024, 'Prognostic Value of Main Pulmonary Artery Diameter in Pulmonary Arterial Hypertension', Heart, Lung and Circulation, 33, pp. S282 - S282, http://dx.doi.org/10.1016/j.hlc.2024.06.337
,2023, 'SGLT2 Inhibitor-Induced Ketoacidosis in a Patient Without Diabetes', Diabetes Care, 47, pp. e4 - e5, http://dx.doi.org/10.2337/dc23-1903
,2023, 'THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.733
,2023, 'Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis', Journal of Scleroderma and Related Disorders, 8, pp. 87 - 100, http://dx.doi.org/10.1177/23971983221145639
,2023, 'Pre-operative pulmonary artery pulsatility index does not predict mortality post-cardiac transplantation', Esc Heart Failure, 10, pp. 1980 - 1986, http://dx.doi.org/10.1002/ehf2.14226
,2023, 'Prognostic role of pulmonary impedance estimation to predict right ventricular dysfunction in pulmonary hypertension', ESC Heart Failure, 10, pp. 1811 - 1821, http://dx.doi.org/10.1002/ehf2.14180
,2023, 'Tricuspid Regurgitation After Heart Transplantation: The Cause or the Result of Graft Dysfunction?', Transplantation, 107, pp. 1390 - 1397, http://dx.doi.org/10.1097/TP.0000000000004511
,2023, 'Acute Myocarditis and Pericarditis After mRNA COVID-19 Vaccinations—A Single-Centre Retrospective Analysis', Heart Lung and Circulation, 32, pp. 467 - 479, http://dx.doi.org/10.1016/j.hlc.2023.01.002
,2023, 'Characteristic changes to pulsatile and steady-state load according to pulmonary hypertension classification', Physiological Reports, 11, http://dx.doi.org/10.14814/phy2.15662
,2023, 'Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial', BMJ Open, 13, http://dx.doi.org/10.1136/bmjopen-2022-069641
,2023, 'Acute Vasoreactivity Testing and Outcomes in Pulmonary Arterial Hypertension: A Call for Increased Testing', Heart Lung and Circulation, 32, pp. 156 - 165, http://dx.doi.org/10.1016/j.hlc.2022.09.005
,2023, 'Heart Transplantation from DCD Donors in Australia: Lessons Learned from the First 74 Cases', Transplantation, 107, pp. 361 - 371, http://dx.doi.org/10.1097/TP.0000000000004294
,2023, 'Acute Myocarditis and Pericarditis After M-RNA COVID-19 Vaccinations—A Single-Centre Retrospective Analysis', Heart, Lung and Circulation, 32, pp. S265 - S265, http://dx.doi.org/10.1016/j.hlc.2023.06.334
,2023, 'Combined Plasmapheresis and Complement Inhibition in a Highly Allosensitised Cardiac Transplant Recipient', Heart, Lung and Circulation, 32, pp. S147 - S148, http://dx.doi.org/10.1016/j.hlc.2023.06.057
,2023, 'Discrepancies in the Clinical and Histopathological Diagnosis of Cardiomyopathy in a Heart Transplant Cohort', Heart, Lung and Circulation, 32, pp. S152 - S152, http://dx.doi.org/10.1016/j.hlc.2023.06.068
,2023, 'Intensive Tacrolimus Level Monitoring After Itraconazole Prophylaxis Cessation Reduces Acute Cellular Rejection Following Heart Transplant', Heart, Lung and Circulation, 32, pp. S164 - S164, http://dx.doi.org/10.1016/j.hlc.2023.06.095
,2023, 'Routine Donor-Specific Antibody Monitoring in Heart Transplant Recipients: Is There a Role?', Heart, Lung and Circulation, 32, pp. S176 - S176, http://dx.doi.org/10.1016/j.hlc.2023.06.122
,2023, 'Turning Back The Clock; A Unique Case of Reversible Pulmonary Hypertension', JOURNAL OF HEART AND LUNG TRANSPLANTATION, 42, pp. S370 - S370
,2022, 'Pulmonary haemodynamics and pulmonary congestion: where are we now?', European Heart Journal, 43, pp. 4515, http://dx.doi.org/10.1093/eurheartj/ehac499
,2022, 'Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis', Internal Medicine Journal, 52, pp. 1826 - 1830, http://dx.doi.org/10.1111/imj.15926
,2022, 'Portopulmonary Hypertension: The Interplay Between the Liver and Pulmonary Arteries', Heart Lung and Circulation, 31, pp. 1185 - 1187, http://dx.doi.org/10.1016/j.hlc.2022.07.010
,2022, 'Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation', Circulation, 145, pp. 1811 - 1824, http://dx.doi.org/10.1161/CIRCULATIONAHA.121.057006
,2022, 'Impact of frailty on mortality and morbidity in bridge to transplant recipients of contemporary durable mechanical circulatory support', Journal of Heart and Lung Transplantation, 41, pp. 829 - 839, http://dx.doi.org/10.1016/j.healun.2022.02.008
,2022, 'Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study (Front Pharmacol., (2022), 12, 811700, 10.3389/fphar.2021.811700)', Frontiers in Pharmacology, 13, http://dx.doi.org/10.3389/fphar.2022.891907
,2022, 'The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension', Pulmonary Circulation, 12, http://dx.doi.org/10.1002/pul2.12069
,2022, 'The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study', Frontiers in Pharmacology, 12, http://dx.doi.org/10.3389/fphar.2021.811700
,2022, 'Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort', Internal Medicine Journal, 52, pp. 69 - 78, http://dx.doi.org/10.1111/imj.15072
,2022, 'Validation of Cognitive Impairment in Combination with Physical Frailty as a Predictor of Mortality in Patients with Advanced Heart Failure Referred for Heart Transplantation', Transplantation, 106, pp. 200 - 209, http://dx.doi.org/10.1097/TP.0000000000003669
,2022, 'HIGH OUTPUT HEART FAILURE: A COMPLEX CASE OF AV MALFORMATION AND MULTI-ORGAN FAILURE', Journal of the American College of Cardiology, 79, pp. 2669 - 2669, http://dx.doi.org/10.1016/s0735-1097(22)03660-9
,2022, 'Impact of Initial Therapeutic Strategy on Long-Term Outcomes in Pulmonary Arterial Hypertension: An Analysis of the PHSANZ Registry', Heart, Lung and Circulation, 31, pp. S86 - S86, http://dx.doi.org/10.1016/j.hlc.2022.06.095
,2021, 'Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry', Respirology, 26, pp. 1171 - 1180, http://dx.doi.org/10.1111/resp.14162
,2021, 'Impact of left heart disease risk factors on risk stratification and treatment response in pulmonary arterial hypertension', EUROPEAN HEART JOURNAL, 42, pp. 1958 - 1958, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000720456902159&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2021, 'Waitlist and post-transplant outcomes for eisenmenger syndrome: A comparison of transplant strategies', Journal of Heart and Lung Transplantation, 40, pp. 841 - 849, http://dx.doi.org/10.1016/j.healun.2021.04.005
,2021, 'Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)', JACC: Heart Failure, 9, pp. 301 - 313, http://dx.doi.org/10.1016/j.jchf.2021.01.007
,2021, 'Pulmonary Vascular Disease as a Systemic and Multisystem Disease', Clinics in Chest Medicine, 42, pp. 167 - 177, http://dx.doi.org/10.1016/j.ccm.2020.11.001
,2021, 'Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry', Respiratory Medicine, 178, http://dx.doi.org/10.1016/j.rmed.2020.106220
,2021, 'The impact of frailty on mortality after heart transplantation', Journal of Heart and Lung Transplantation, 40, pp. 87 - 94, http://dx.doi.org/10.1016/j.healun.2020.11.007
,